Another notch on cancer's belt

Italian researchers have identified peptidyl prolyl isomerase as a new player in the Notch signaling pathway that could be targeted to help treat cancer.¹ The findings potentially open a new avenue for cancer therapies with fewer side effects than compounds that hit other members of the Notch pathway.

Signaling through the Notch family of receptors helps regulate cell fate and cell proliferation in many developmental processes,² and dysfunction of Notch signaling has been implicated in multiple cancers.^3-5...